title: Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
abstract: Direct oral anticoagulants (DOACs) specifically target factor IIa or Xa and represent a major step forward in the treatment of acute- and long-term prevention of venous thrombo-embolism (VTE). They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring. These antithrombotic agents introduce a new paradigm for the day-to-day management of VTE. Direct oral anticoagulants should streamline the management of most patients with VTE and will facilitate care in the outpatient setting. Nevertheless, it remains uncertain how to select specific DOACs for particular profiles of patients, and the optimal management of bleeding complications is evolving.
authors: Division of Angiology and Haemostasis, Department of Medical Specialties, Faculty of Medicine and University Hospitals of Geneva, 4, Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland pierre.fontana@hcuge.ch.
authors: Pierre
authors: P
authors: Fontana
authors: Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
authors: Samuel Z
authors: SZ
authors: Goldhaber
authors: Division of Angiology and Haemostasis, Department of Medical Specialties, Faculty of Medicine and University Hospitals of Geneva, 4, Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland.
authors: Henri
authors: H
authors: Bounameaux
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000991:Antithrombins / Q000008:administration & dosage* / Q000494:pharmacology; D001562:Benzimidazoles / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D000069604:Dabigatran; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D008134:Long-Term Care; D009025:Morpholines / Q000008:administration & dosage; D019990:Perioperative Care / Q000379:methods; D011655:Pulmonary Embolism / Q000517:prevention & control; D011720:Pyrazoles / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D011728:Pyridones / Q000008:administration & dosage; D000069552:Rivaroxaban; D013844:Thiazoles / Q000008:administration & dosage; D013876:Thiophenes / Q000008:administration & dosage; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors; D015091:beta-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000991:Antithrombins; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; D013876:Thiophenes; D015091:beta-Alanine; D014812:Vitamin K; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran; C552171:edoxaban
keywords: Anticoagulant; Deep venous thrombosis; Direct factor Xa inhibitors; Direct thrombin inhibitors; Pulmonary embolism